CRA analyzed market definition in antitrust litigation concerning a product in the non-opioid pain category. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing.
Insights from the final panel at the CRA Brussels Conference 2025: Shaping the future of digital regulation and competition
The closing panel from 2025 CRA Brussels Conference, “Digital Regulation in Action: The DMA, AI, and the Future of Competition” moderated by Dr Matteo Foschi